Skip to main content
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. — Investor Relations & Filings

Ticker · CMMB ISIN · US16385C1045 US Manufacturing
Open in API
Filings indexed 332 across all filing types
Latest filing 2021-04-14 Regulatory Filings
Country US United States of America
Listing US CMMB

About Chemomab Therapeutics Ltd.

https://www.chemomab.com/

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's scientific platform is based on the discovery of the soluble protein CCL24's central role in driving the cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class monoclonal antibody designed to neutralize CCL24, thereby interfering with the primary pathways that promote these conditions. Nebokitug has demonstrated disease-modifying potential in multiple clinical trials and has received Orphan Drug and Fast Track designations from the U.S. FDA for the treatment of primary sclerosing cholangitis (PSC). Following positive Phase 2 results, the company is preparing for a potential Phase 3 trial for nebokitug in PSC.

Recent filings

Filing Released Lang Actions
FORM 8-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A filing, which is an amendment to a Current Report on Form 8-K. It discusses the closing of a merger transaction and includes pro forma financial statements related to the merger. The document references prior filings such as the Annual Report on Form 10-K and a Registration Statement on Form S-3. The content focuses on updating disclosures related to the merger and the company's business overview, pipeline, and clinical studies. There are no full financial statements or comprehensive financial performance data typical of an Annual Report or Interim Report. The document is a regulatory filing updating prior disclosures and providing merger-related information, consistent with the nature of a Current Report amendment. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-04-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes an amendment to an Asset Purchase and Assignment Agreement, including payment terms and related details. It is not a full financial report, earnings release, or management discussion, but rather a specific event disclosure. The document length is about 5271 characters, which is typical for an 8-K filing. The nature of the content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a material event, not fitting into more specific categories like M&A filings or earnings releases. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-04-05 English
Regulatory Filings 2021
Regulatory Filings
2021-03-30 English
SCHEDULE 13D
Major Shareholding Notification
2021-03-26 English
Director's Dealing 2021
Director's Dealing
2021-03-26 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-03-26 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.